Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolism (for specialized target groups only)

Phase III EINSTEIN-Jr. study in children concludes the largest pediatric thromboembolism program delivering results consistent with those in adults / Study shows a low risk of recurrent venous thromboembolism (VTE) in children treated with rivaroxaban compared with standard of care with low rates of bleeding / First phase III data on the use of a non-vitamin K oral anticoagulant (NOAC) in a large pediatric population / Study investigated a body weight-adjusted oral 20 mg equivalent dose of rivaroxaban for the prevention of recurrent VTE in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news